Karyopharm Therapeutics | KPTI - Stock


Karyopharm Therapeutics reported $4.04M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Abbott USD 6.99B 501M Mar/2026
Amgen USD 6.19B 39M Mar/2026
AstraZeneca USD 6.57B 13M Mar/2026
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Eli Lilly USD 14.53B 785M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Incyte USD 115.62M 14.56M Mar/2026
J&J USD 14.58B 392M Mar/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.48B 179M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Novartis USD 6.29B 17M Mar/2026
Novartis USD 6.42B 114M Sep/2025
Pfizer USD 10.67B 13M Mar/2026
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Takeda JPY 1.41T 107.71B Dec/2025
TG Therapeutics USD 129.03M 3.44M Mar/2026
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026